Table of Contents Title of each class Trading Symbol Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-30347 CURIS, INC. (Exact Name o ...

Curis, Inc. (NASDAQ:CRIS) Q1 2021 Results Conference Call May 12, 2021 4:30 PM ET Company Participants Bill Steinkrauss - Chief Financial Officer Jim Dentzer - President and Chief Executive Officer Bob Martell - Head of Research and Development Conference Call Participants Ed White - H.C. Wainwright Justin Walsh - B. Riley Securities Soumit Roy - JonesTrading Alethia Young - Cantor Fitzgerald Operator Good afternoon and welcome to the Curis' First Quarter 2021 Earnings Call. All participants will be in a li ...

Table of Contents Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $0.01 per share CRIS Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr ...

Corporate Presentation NASDAQ: CRIS Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "expect(s)," "believe(s)," "will," "may," "anticipate(s)," "focus(es)," "plans," "mission," "strategy," "potential," "estimate(s)", "intend," "project," "seek," "should," "would" and similar expressions are int ...

Curis, Inc. (NASDAQ:CRIS) Q4 2020 Earnings Conference Call March 16, 2021 4:30 PM ET Company Participants Jim Dentzer - President and Chief Executive Officer Bill Steinkrauss - Chief Financial Officer Bob Martell - Head of Research and Development Conference Call Participants Alethia Young - Cantor Fitzgerald Ed White - H.C. Wainwright & Co Soumit Roy - JonesTrading Yale Jen - Laidlaw & Company Operator Good afternoon. And welcome to the Curis' Fourth Quarter and Year End 2020 Earnings Call. All participant ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-30347 CURIS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3505116 (State or other jurisdiction of incorpora ...

Curis, Inc. (NASDAQ:CRIS) Q3 2020 Earnings Conference Call November 10, 2020 4:30 PM ET Company Participants Bill Steinkrauss - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Bob Martell - Head of R&D Conference Call Participants Yale Jen - Laidlaw & Company Soumit Roy - JonesTrading Operator Good afternoon everyone and welcome to the Curis' Third Quarter 2020 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After the company’s prep ...

Table of Contents Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $0.01 per share CRIS Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition perio ...

Financial Data and Key Metrics Changes - Curis reported a net loss of $6.7 million or $0.17 per share for Q2 2020, compared to a net loss of $7.2 million or $0.22 per share for the same period in 2019 [25] - Revenues for Q2 2020 were $2.4 million, an increase from $2.1 million in Q2 2019, primarily from royalty revenues related to Erivedge [25] - Operating expenses decreased to $7.8 million in Q2 2020 from $8.2 million in Q2 2019, with R&D expenses at $5.3 million, down from $5.6 million [26] Business Line Data and Key Metrics Changes - The company advanced its IRAK4 program, CA-4948, in ongoing studies for non-Hodgkin's lymphoma and initiated a second study for acute myeloid leukemia [6][7] - The enrollment pace for the Phase I study of CA-4948 slowed due to COVID-19, but sites have reopened and are actively enrolling patients [10] - The company plans to initiate a combination study of CA-4948 with ibrutinib, leveraging preclinical data showing significant anticancer benefits [11][12] Market Data and Key Metrics Changes - The company received FDA clearance for its investigational new drug application for CI-8993, a monoclonal anti-VISTA antibody, marking a significant milestone in its pipeline [7][24] - The competitive landscape in oncology is evolving, with Curis focusing on the unique targeting of IRAK4-L, a key driver of disease in AML and MDS [46][47] Company Strategy and Development Direction - Curis aims to develop targeted cancer therapies addressing unmet patient needs, with a focus on advancing its clinical pipeline and achieving data catalysts in the near future [5][8] - The company is strategically pursuing both monotherapy and combination therapy approaches in its clinical studies, particularly in indications where ibrutinib is used [39][56] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of COVID-19 on clinical trial enrollment but expressed confidence in resuming progress and achieving key milestones by year-end [30] - The focus for the remainder of the year is on safety data for CI-8993, with efficacy data expected in the following year [62][66] Other Important Information - As of June 30, 2020, Curis had cash, cash equivalents, and investments totaling $23.6 million, expected to support operations into the first half of 2021 [28] - The company anticipates maintaining a cash burn of $7 million to $8 million per quarter for the remainder of the year [69] Q&A Session Summary Question: Impact of COVID on CA-4948 data release - Management confirmed that COVID-19 affected enrollment but expressed confidence in finalizing Phase II dosing by year-end [30] Question: Dose level for CA-4948 and ibrutinib combination - The company plans to start the combination study with a therapeutic dose of 200 mg, with potential for dose escalation based on patient response [32] Question: Rate-limiting factors for anti-VISTA program - Management indicated no significant rate-limiting factors, with productive discussions with the FDA facilitating rapid progress [33] Question: Patient demographics in NHL studies - Enrollment includes a diverse mix of relapsed/refractory patients, averaging 3.5 lines of prior therapy [36] Question: Competitive landscape for AML and MDS - Management acknowledged evolving treatment algorithms and emphasized the unique targeting of IRAK4 as a key component in treating these diseases [42][46] Question: Future data release venues - The company aims to release data at medical conferences, with plans for top-line information followed by detailed presentations [50] Question: Focus on DLBCL in future studies - Management plans to pursue both DLBCL and other indications where ibrutinib is used, based on preclinical data supporting synergy [56][58] Question: Safety focus for CI-8993 - The emphasis for this year is on safety management, particularly regarding cytokine release syndrome [62][66] Question: Operating expenses guidance - Management expects operating expenses to remain consistent in the second half of the year, with a cash burn estimate of $7 million to $8 million per quarter [69]

Table of Contents Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $0.01 per share CRIS Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro ...